IL-17 (Interleukin-17) is a family of proinflammatory cytokines that mediate normal inflammatory and immune responses, also it has the most prominent role in host defense and autoimmunity. IL-17 binds to IL-17 receptors which are expressed in various cell types. The IL-17 signaling pathway promotes angiogenesis and the release of proinflammatory cytokines, chemokines, and mediators of tissue damage. IL-17 inhibitors act by preventing the interaction of IL-17 with the IL-17 receptor and also the activation of the IL-17 receptor signaling pathway associated with inflammatory processes. IL-17 inhibitors are marketed for conditions including ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, and others. Novartis, Eli Lilly & Company, Bausch Health, Biocad, AbbVie, Roche, Merck (MSD), J&J, and LEO Pharma are some of the major players in the IL-17 inhibitors market.
Key Market Developments:
- In Oct 2022, NovaRock Biotherapeutics entered into a licensing agreement with Shanghai JMT-Bio Technology for NBL 012, an IL-17 inhibitor.
- In Jun 2023, USB registered Bimekizumab for Axial spondyloarthritis and psoriatic arthritis in the European Union.
Approved Drug Molecules and Brand Names for IL-17 Modulators:
- Siliq (Brodalumab)
- Arcalyst (Rilonacept)
- Cosentyx (Secukinumab)
- Simulect (Basiliximab)
- Stelara (Ustekinumab)
- Dupixent (Dupilumab)
- Taltz (Ixekizumab)
- Bimzelx (Bimekizumab)
- Efleira (Netakimab)
- Virulizin (Bovine bile tissue extract)
- Remicade (Infliximab)
Drugs under the Pipeline for IL-17 Modulators:
- Vidofludimus (IMU-838)
- Vunakizumab (SHR-1314)
- Izokibep (ABY-035)
- CJM112
- Remtolumab (ABT-122)
- JS005
- MOR106
- Gumokimab (AK111)
- Isomyosamine (MYMD-1)
- Sonelokimab (M1095)
- Tibulizumab (ZB-106)
- CNTO6785
- HB0017
- KIO-101
- Afasevikumab (NI 1401)
- BAT2306 (Secukinumab biosimilar)
- Jinlixi (Xeligekimab)
- LY3509754
- SCH900117
- Izumerogant (IMU-935)
- Perakizumab (RG4934)
- BITS7201A
- DC-806
- JNJ-61178104
- LP0200
- NBL-012
- SCT650C
- SFA-002
- SM17
- XKH001
- ZL-1102
- Anti-TNF/IL-17A FynomAB (COVA322)
Clinical Activity and Developments of IL-17 Modulators:
At present, there are about 39 drug products in IL-17 inhibitors, among which 12 of them are in the market for treatments of various disease conditions, and the rest are in clinical development phases.
- In Jan 2023, SFA Therapeutics completed enrolment in its phase-Ib trial for plaque psoriasis in early 2023 for SFA-002, an IL-17 modulator.
- In Feb 2023, Biocad conducted phase-I/II clinical trials in spinal muscular atrophy in Russia for ANB-004, an IL-17 modulator.
|
Molecule Name |
Number of Studies |
|
Vidofludimus (IMU-838) |
12 |
|
Vunakizumab (SHR-1314) |
12 |
|
Izokibep (ABY-035) |
9 |
|
CJM112 |
6 |
|
Remtolumab (ABT-122) |
5 |
|
JS005 |
4 |
|
MOR106 |
4 |
|
Gumokimab (AK111) |
4 |
|
Isomyosamine (MYMD-1) |
4 |
|
Sonelokimab (M1095) |
4 |
|
Tibulizumab (ZB-106) |
4 |
|
608 |
3 |
|
CNTO6785 |
3 |
|
HB0017 |
3 |
|
KIO-101 |
3 |
|
Afasevikumab (NI 1401) |
3 |
|
BAT2306 (Secukinumab biosimilar) |
2 |
|
Jinlixi (Xeligekimab) |
2 |
|
LY3509754 |
2 |
|
SCH900117 |
2 |
|
Izumerogant (IMU-935) |
2 |
|
Perakizumab (RG4934) |
2 |
|
BITS7201A |
2 |
|
DC-806 |
1 |
|
JNJ-61178104 |
1 |
|
LP0200 |
1 |
|
NBL-012 |
1 |
|
SCT650C |
1 |
|
SFA-002 |
1 |
|
SM17 |
1 |
|
XKH001 |
1 |
|
ZL-1102 |
1 |
|
anti-TNF/IL-17A FynomAB (COVA322) |
1 |
Target Indication Analysis of IL-17 Modulators
IL-3 inhibitors such as Secukinumab, Basiliximab, Ustekinumab, Dupilumab, Ixekizumab, and others are used in the treatment of ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, and others. Some of them have also been registered for hidradenitis suppurativa and juvenile rheumatoid arthritis, are in phase III for giant cell arteritis, graves ophthalmology, lupus nephritis, polymyalgia rheumatica, and rotator cuff injuries, in phase II for atopic dermatitis, necrobiosis lipoidica, pyoderma gangrenosum, varicose ulcer, and others.
Regional Analysis of IL-17 Modulators
IL-17 Modulators Market
The autoimmune diseases affect as much as 4.5 percent of the world’s population. Psoriasis and rheumatoid arthritis are the most commonly occurring autoimmune diseases. According to the Autoimmune Registry Inc (ARI) report 2020, about 15 to 30 million people in the USA suffer from autoimmune disease, which primarily affects women aged 20 to 40. The growing burden of autoimmune diseases indicates the market growth potential for IL-3 inhibitors. Eli Lilly & Company’s Taltz had a total sale of US$ 2,482 million in 2022, where the sale alone in the USA was US$ 1,724 million. Novartis’s Cosentyx (US$ 4.8 billion) sales grew in emerging growth markets, Europe, China, and Japan, and all of its patents will expire in 2031.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Siliq (Brodalumab), Arcalyst (Rilonacept), Cosentyx (Secukinumab), Simulect (Basiliximab), Stelara (Ustekinumab), Dupixent (Dupilumab) are the few approved IL-17 Modulators.
Novartis, Eli Lilly & Company, Bausch Health, Biocad, AbbVie, Roche, Merck (MSD), J&J, and LEO Pharma are some of the major players in the IL-17 inhibitors market.
Major indications for IL-17 modulators are ankylosing spondylitis, non-radiographic axial spondylarthritis, plaque psoriasis, psoriatic arthritis, and pustular psoriasis.
There are a total of 31 molecules in clinical development phases for IL-17 modulators.
- Novartis
- Eli Lilly & Company
- Bausch Health
- UCB
- Jiangsu Hengrui Pharma
- Biocad
- AbbVie
- Shanghai Junshi Bioscience
- Akesobio
- Roche
- Bio-Thera Solutions
- Merck (MSD)
- DICE Therapeutics
- J&J
- LEO Pharma
- CSPC Pharma
- Kanova Biopharma